Richard L. Plotkin
In 2015, Richard Plotkin came out of retirement and joined EPSTEIN OSTROVE, LLC as Of Counsel, looking to add to his almost 40 years of practicing law. Richard had spent the first part of his career, which spanned from 1970 until 2008, in the complex commercial litigation department of a large regional law firm. His practice focused on all facets of commercial litigation, including cases such as unfair competition, restrictive covenants, real estate broker litigation, and other real estate related litigation, such as commercial landlord/tenant disputes and property tax appeals of commercial properties. He continued that practice and focus with EPSTEIN OSTROVE, LLC.
Richard was frequently recognized for his contributions to the legal community. For example, he was appointed by the Supreme Court of New Jersey to serve on the Supreme Court Committee on Taxation, dealing with the issue of state and local taxes in New Jersey. He was also appointed by the Superior Court, Chancery Division, Morris County, to Chair its mediation panel, which he did from 1996 until his original retirement in December, 2008. Richard was recognized by several publications, as well, including Best Lawyers and New Jersey Super Lawyers.
Upon his original retirement from the practice of law in 2008, Richard became the Vice Chairman/Co-Founder of the Max Cure Foundation, a 501(c)(3) pediatric cancer foundation that he started in December, 2008, with his son, David, following the diagnosis of his grandson, Max Plotkin, at age 3, of cancer. Max is now considered childhood cancer survivor. Richard oversaw all operations and initiatives to execute the three-fold mission of MCF: to fund research; to financially assist low income and military families battling cancer in their children; and to advocate for children with cancer and their families. Richard was a tireless advocate for pediatric cancer issues and a major force in advocating for children with cancer. His accomplishments include, but are certainly not limited to:
• Richard was credited with having, single handedly, caused the issuance by the Federal Drug Administration (FDA) of the first compassionate use waiver for a child with cancer of a combination drug therapy consisting of an experimental drug and two drugs that had already received FDA approval and were in the marketplace.
• He was appointed to a special committee consulting with the White House on pediatric cancer issues.
• He was credited by Congressman Michael McCaul, (R., Texas), Co-Chairman of the Congressional Caucus on Pediatric Cancer, with playing a major role in the passage in July, 2012, of the Creating Hope Act, which incentivizes pharmaceutical companies to invest resources to develop drugs for rare children’s diseases, including cancer.
• He was selected during the summer of 2013 as the Patient Advocate (representing pediatric cancer patients) on a Committee formed by the NYU Langone Medical Center, Department of Medical Ethics, which is studying the current system under which the FDA issues compassionate use waivers for the purpose of allowing experimental drugs and medical devices to be given to terminally and/or seriously ill patients for the purpose of determining if the existing system needs to be changed.
• He was consulted by the co-sponsors of legislation pending in Congress dealing with the issue of permitting terminally ill and seriously ill patients to receive unapproved drugs to treat their diseases under compassionate use waivers sought from the FDA.
Richard held a B.S. in Economics from the Wharton Business School of the University of Pennsylvania and a J.D. degree from Georgetown Law Center.